LUPIN2,074.00

Lupin Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMACIPLADRREDDYALKEMFORTISAUROPHARMALAURUSLABSMANKINDMcap ₹94,823 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Total Debt2,669.95,076.75,910.25,910.2
Net Debt839.72,473.9-1,834.7-1,834.7
Total Debt/Equity0.190.290.260.26
Net Debt/Equity0.060.14-0.08-0.08
Total Debt/EBITDA0.700.960.670.67
Net Debt/EBITDA0.220.47-0.21-0.19
Interest Coverage (EBIT/Interest)8.3913.9517.1217.12
Total Debt/Total Capital %15.6722.6920.7920.79
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.